Catalent to Expand its Argentinian Site
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.
Catalent announced on August 4, 2020 that it is expanding its Argentinian site in Loma Hermosa, Buenos Aires, Argentina, to accommodate more than 11,000 ft2 of production space to handle cytotoxic and highly active products for prescription softgel manufacturing.
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site, a company press release said. The facility is expected to be completed in December 2021.
“This investment will allow the site to grow and handle a wider range of projects, reacting to the increased demands of the industry for high potency treatments in areas such as oncology,” commented Sergio Alter, vice president and general manager, Softgel Technologies, Latin America, in the press release. “Not only will this increase the capacity of the site, but the design of the new facility will see it meet the highest standards of environmental and energy efficiency.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
